Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway

被引:35
作者
Hilbert, DM
Migone, TS
Kopf, M
Leonard, WJ
Rudikoff, S
机构
[1] NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892
[2] BASEL INST IMMUNOBIOL,CH-4005 BASEL,SWITZERLAND
关键词
D O I
10.1016/S1074-7613(00)80312-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of murine plasma cell tumors induced by raf/myc containing retroviruses is facilitated by T cells and completely dependent on IL-6. To determine whether kinases with differing specificities reflect alternative biochemical pathways in B cell tumorigenesis, we have employed an abl/myc containing retrovirus to assess neoplastic development. In contrast with raf/myc, abl/myc disease is T cell and IL-6 independent. An examination of the IL-6 signal transduction pathway reveals that this pathway, as defined by activation of Stat3, is inducible by IL-6 in raf/myc tumors but constitutively activated in abl/myc tumors. These findings provide a mechanism for the derivation of cytokine-independent plasma cell tumors and suggest that both IL-6-dependent and independent tumors may arise in vivo depending on the particular mutational events incurred during tumorigenesis.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 77 条
  • [1] MOLECULAR-CLONING OF APRF, A NOVEL IFN-STIMULATED GENE FACTOR-3 P91-RELATED TRANSCRIPTION FACTOR INVOLVED IN THE GP130-MEDIATED SIGNALING PATHWAY
    AKIRA, S
    NISHIO, Y
    INOUE, M
    WANG, XJ
    WEI, S
    MATSUSAKA, T
    YOSHIDA, K
    SUDO, T
    NARUTO, M
    KISHIMOTO, T
    [J]. CELL, 1994, 77 (01) : 63 - 71
  • [2] INDUCTION OF PLASMA CELL TUMOURS IN BALB/C MICE WITH 2,6,10,14-TETRAMETHYLPENTADECANE (PRISTANE)
    ANDERSON, PN
    POTTER, M
    [J]. NATURE, 1969, 222 (5197) : 994 - &
  • [3] BAST EJEG, 1982, CLIN EXP IMMUNOL, V47, P677
  • [4] INTERLEUKINS AND IGA SYNTHESIS - HUMAN AND MURINE INTERLEUKIN-6 INDUCE HIGH-RATE IGA SECRETION IN IGA-COMMITTED B-CELLS
    BEAGLEY, KW
    ELDRIDGE, JH
    LEE, F
    KIYONO, H
    EVERSON, MP
    KOOPMAN, WJ
    HIRANO, T
    KISHIMOTO, T
    MCGHEE, JR
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (06) : 2133 - 2148
  • [5] INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA
    BERGUI, L
    SCHENA, M
    GAIDANO, G
    RIVA, M
    CALIGARISCAPPIO, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) : 613 - 618
  • [6] BILLADEAU D, 1992, BLOOD, V80, P1818
  • [7] THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL
    BILLADEAU, D
    AHMANN, G
    GREIPP, P
    VANNESS, B
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) : 1023 - 1031
  • [8] THE PLASMACYTOMA GROWTH INHIBITOR RESTRICTIN-P IS AN ANTAGONIST OF INTERLEUKIN-6 AND INTERLEUKIN-11 - IDENTIFICATION AS A STROMA-DERIVED ACTIVIN-A
    BROSH, N
    STERNBERG, D
    HONIGWACHSSHAANANI, J
    LEE, BC
    SHAV-TAL, Y
    TZEHOVAL, E
    SHULMAN, LM
    TOLEDO, J
    HACHAM, Y
    CARMI, P
    JIANG, W
    SASSE, J
    HORN, F
    BURSTEIN, Y
    ZIPORI, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) : 29594 - 29600
  • [9] CASSEL A, 1990, EXP HEMATOL, V18, P1171
  • [10] JAK-STAT SIGNALING INDUCED BY THE V-ABL ONCOGENE
    DANIAL, NN
    PERNIS, A
    ROTHMAN, PB
    [J]. SCIENCE, 1995, 269 (5232) : 1875 - 1877